Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2012
11/07/2012CN101935687B Application of IL-12p40 siRNA to promoting liver regeneration
11/07/2012CN101891817B Monoclonal antibody capable of preventing high mobility group box-1 (HMGB-1) and application thereof
11/07/2012CN101891814B Anti-osteopontin OPN monoclonal antibody and application thereof
11/07/2012CN101843899B Methicillin-resistant staphylococcus aureus (MRSA) recombinant multivalent subunit genetic engineering vaccine and method for preparing same
11/07/2012CN101838319B Asia 1-type FMDV compound multiepitope
11/07/2012CN101721699B Application of VEGF receptor fusion protein in preparing medicament for treating inflammatory reaction accompanying increase of VEGF
11/07/2012CN101678101B Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukemia
11/07/2012CN101671654B Monoclonal antibody resisting anaplasma marginale MSP5 protein and application thereof
11/07/2012CN101469017B Synthetic peptide vaccines for foot-and-mouth disease
11/07/2012CN101194012B Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
11/06/2012US8304396 Immunostimulatory nucleic acids
11/06/2012US8304258 Methods of producing monoclonal antibodies specific for human hepcidin
11/06/2012US8304234 Compositions and methods for delivery of genetic material
11/06/2012US8304220 Bone semi-permeable device
11/06/2012US8303964 Viable non-toxic gram-negative bacteria
11/06/2012US8303963 Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same
11/06/2012US8303962 Antibacterial and antifungal peptides
11/06/2012US8303961 Borrelia antigens
11/06/2012US8303959 Compositions and methods for detection of antibodies specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl)
11/06/2012US8303958 Method of treating immunological disorders by administering truncated BAFF receptors
11/06/2012US8303957 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof
11/06/2012US8303956 Glycosylated specificity exchangers
11/06/2012US8303955 Humanized anti-CD40 antibodies and their methods of use
11/06/2012US8303954 Anti-Aβ oligomer humanized antibody
11/06/2012US8303953 Antibody molecules which bind IL-17A and IL-17F
11/06/2012US8303952 Methods for inducing in vivo tolerance
11/06/2012US8303951 Neutrokine-alpha antibodies and methods of use thereof
11/06/2012CA2545359C Compositions and methods for regulation of tumor necrosis factor-alpha
11/06/2012CA2521909C Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form
11/06/2012CA2494379C Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
11/06/2012CA2493083C Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors
11/06/2012CA2450939C Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
11/06/2012CA2393467C Chordin-like molecules and uses thereof
11/06/2012CA2365533C Diagnosis and treatment of neuroectodermal tumors
11/06/2012CA2305630C Soluble single-chain t-cell receptor proteins
11/01/2012WO2012149536A1 Neutralizing antibodies to nipah and hendra virus
11/01/2012WO2012149454A2 Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use
11/01/2012WO2012149419A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
11/01/2012WO2012149416A2 Human myeloid derived suppressor cell cancer markers
11/01/2012WO2012149412A2 Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof
11/01/2012WO2012149406A2 Assessing and treating humans with long qt syndrome
11/01/2012WO2012149405A2 Tolerogenic synthetic nanocarriers for regulating innate immune responses
11/01/2012WO2012149404A2 Liquid vaccine preparations
11/01/2012WO2012149393A2 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
11/01/2012WO2012149365A2 Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
11/01/2012WO2012149364A1 Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
11/01/2012WO2012149358A1 Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
11/01/2012WO2012149356A2 Anti-cd40 antibodies and methods of use
11/01/2012WO2012149334A2 Methods and compositions for the generation and use of conformation-specific antibodies
11/01/2012WO2012149307A2 Synthetic long peptide (slp)-based vaccines
11/01/2012WO2012149301A2 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012WO2012149282A2 Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells
11/01/2012WO2012149268A1 Tolerogenic synthetic nanocarriers for allergy therapy
11/01/2012WO2012149265A2 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012WO2012149259A1 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012WO2012149255A2 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012WO2012149252A2 Tolerogenic synthetic nanocarriers
11/01/2012WO2012149247A2 Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use
11/01/2012WO2012149228A1 Compositions and method for treating autoimmune diseases
11/01/2012WO2012149160A2 Viruses modified with unnatural moieties and methods of use thereof
11/01/2012WO2012149045A2 Liposomal formulations
11/01/2012WO2012149038A1 Truncated hiv envelope proteins (env), methods and compositions related thereto
11/01/2012WO2012148708A1 Modified sendai virus vaccine and imaging vector
11/01/2012WO2012148547A1 Compositions and methods for treating inflammatory conditions of the ocular surface
11/01/2012WO2012148538A2 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
11/01/2012WO2012148046A1 Anticancer and cancer-sensitizing composition comprising rrp12 inhibitor
11/01/2012WO2012148003A1 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
11/01/2012WO2012147800A1 Composition for predicting sensitivity to trastuzumab therapy in breast cancer patients and method using same
11/01/2012WO2012147713A1 Anti-b7-h3 antibody
11/01/2012WO2012147053A1 A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
11/01/2012WO2012146628A1 Novel immunoconjugates
11/01/2012WO2012146394A1 Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
11/01/2012WO2012146364A1 Microparticle and/or nanoparticle vaccine for prophylactic and/or therapeutic application
11/01/2012WO2012145925A1 Uses of food allergens and antibodies thereof in iga nephropathy
11/01/2012WO2012122359A3 Target directed to adipocytes, methods and assays for treatment of obesity
11/01/2012WO2012121528A3 Magnetic nanocomposite specific for thyroid cancer and use thereof
11/01/2012WO2012114312A3 Exogenous internal positive control
11/01/2012WO2012109373A3 Treatment of osteoarthritis and pain
11/01/2012WO2012109243A3 Method of treating intercellular barrier dysfunction
11/01/2012WO2012106473A3 Dosing for treatment with anti-egfl7 antibodies
11/01/2012WO2012103282A3 Methods and compositions for treating alzheimer's disease
11/01/2012WO2012088001A3 Antiviral activity of bovine type iii interferon against foot-and-mouth disease virus
11/01/2012WO2012075340A3 Anti-ngf compositions and use thereof
11/01/2012WO2012061374A3 Dual variable domain immunoglobulins and uses thereof
11/01/2012US20120277573 Ultrasound-activated nanoparticles as imaging agents and drug delivery vehicles
11/01/2012US20120277221 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
11/01/2012US20120277166 Conotoxin peptides useful as inhibitors of neuronal amine transporters
11/01/2012US20120276613 Modified vaccinia ankara virus variant and cultivation method
11/01/2012US20120276193 Agents, Uses and Methods
11/01/2012US20120276192 Compositions and methods for sirna inhibition of icam-1
11/01/2012US20120276191 Treatment and Diagnosis of Macrophage Mediated Disease
11/01/2012US20120276190 Therapy with a chimeric molecule and a pro-apoptotic agent
11/01/2012US20120276167 Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
11/01/2012US20120276160 Tolerogenic synthetic nanocarriers for regulating innate immune responses
11/01/2012US20120276159 Tolerogenic synthetic nanocarriers
11/01/2012US20120276158 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012US20120276157 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012US20120276156 Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use
11/01/2012US20120276155 Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
11/01/2012US20120276146 Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea
1 ... 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 ... 1823